Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX

• Main Authors: Suvasini Ramaswamy, Nina Tonnu, Tushar Menon, Benjamin M. Lewis, Kevin T. Green, Derek Wampler, Paul E. Monahan, Inder M. Verma
• Format: Article
• Language: English
• Published: Elsevier 2018-05-01
• Series: Cell Reports
• Online Access: http://www.sciencedirect.com/science/article/pii/S2211124718304972

Summary: Hemophilia B is an ideal target for gene- and cell-based therapies because of its monogenic nature and broad therapeutic index. Here, we demonstrate the use of cell therapy as a potential long-term cure for hemophilia B in our FIX-deficient mouse model. We show that transplanted, cryopreserved, cadaveric human hepatocytes remain functional for more than a year and secrete FIX at therapeutic levels. Hepatocytes from different sources (companies and donors) perform comparably in curing the bleeding defect. We also generated induced pluripotent stem cells (iPSCs) from two hemophilia B patients and corrected the disease-causing mutations in them by two different approaches (mutation specific and universal). These corrected iPSCs were differentiated into hepatocyte-like cells (HLCs) and transplanted into hemophilic mice. We demonstrate these iPSC-HLCs to be viable and functional in mouse models for 9–12 months. This study aims to establish the use of cells from autologous and heterologous sources to treat hemophilia B. : Ramaswamy et al. show that hepatocytes transplanted into a mouse model can alleviate symptoms of hemophilia B. Induced pluripotent cells from patients with hemophilia B can be gene-corrected and converted to hepatocyte-like cells for cell therapy. This provides evidence for potential treatment of monogenic diseases of the liver using cell therapy. Keywords: cell therapy, hemophilia, liver, iPSc derived hepatocyte-like cells, autologous cell therapy, heterologous cell therapy, monogenic liver diseases